Full-Text Search:
Home|About CNKI|User Service|中文
Add to Favorite Get Latest Update

Drug resistance to nucleoside and nucleotide analogs in chronic hepatitis B and its management

Experts Attending the Discussion on Hepatitis B Virus Drug Resistance Corresponding ZHUANG Hui,Department of Microbiology and Infectious Disease Center, School of Basic Medical Sciences,Peking University Health Science Center,Beijing 100191,China  
Four nucleos(t)ide analogs(NAs)have been approved by the Food and Drug Administration,China for treatment of patients with chronic hepatitis B(CHB).The patients can be successfully treated using nucleos(t)ide analogs(NAs),but drug-resistant hepatitis B virus(HBV)mutants frequently arise,leading to treatment failure and progression of the disease.This paper has reviewed the mechanisms of resistance to NAs,and consensus on the management and prevention of HBV resistance to NAs.
Download(CAJ format) Download(PDF format)
CAJViewer7.0 supports all the CNKI file formats; AdobeReader only supports the PDF format.
©CNKI All Rights Reserved